QTc Not Prolonged by Onartuzumab Plus Paclitaxel With or Without Bevacizumab
the Cancer Therapy Advisor take:
According to a new study published in the journal Cancer Chemotherapy and Pharmacology, researchers have found that onartuzumab, when given in combination with weekly paclitaxel with or without bevacizumab, does not prolong the corrected QT (QTc) interval.
In the phase 2 study, 185 patients with locally recurrent or metastatic triple-negative breast cancer were randomly assigned to receive onartuzumab or placebo, with or without bevacizumab in combination with weekly paclitaxel as first- or second-line therapy. The aim of the study was to evaluate the effect of the regimen on patients' QTc intervals and other electrocardiogram (ECG) parameters.
Patients received a triplicate 12-lead ECG before and after each dose on day 1 of cycles 1, 2, and 4, and at the time of drug discontinuation. Onartuzumab serum samples were also collected from patients. Results showed that among the 165 patients who had ECG-evaluable data, similar changes in QTc were observed across all treatment groups.
In addition, researchers observed similar changes in PR interval, QRS duration, and heart rate across all treatment arms. No association was found between onartuzumab serum concentration and change in QTc interval. Onartuzumab is an investigational humanized anti-MET monoclonal antibody currently being studied in a variety of cancer types.
Onartuzumab with weekly paclitaxel with or without bevacizumab does not prolong the corrected QT interval.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer